Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfad is a phytopharmaceutical herbal supplement developed by Pharma Pharmaceutical Industries (PPI). It is formulated as an oral tablet containing a synergistic combination of four bioactive herbal extracts: artichoke (*Cynara scolymus*), turmeric (*Curcuma longa*), liquorice (*Glycyrrhiza glabra*), and milk thistle (*Silybum marianum*). The product is primarily indicated for the support and protection of liver and digestive health, particularly in individuals susceptible to fatty liver conditions such as those who are overweight. While the specific molecular mechanisms are complex and not fully defined, the ingredients are traditionally recognized for their hepatoprotective, antioxidant, and choleretic properties. Sulfad is manufactured using ingredients sourced from Italy and is marketed in the Middle East region, typically taken as a once-daily dose.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sulfad.